Oxidative phosphorylation enhances the leukemogenic capacity and resistance to chemotherapy of B cell acute lymphoblastic leukemia

Sci Adv. 2021 Mar 10;7(11):eabd6280. doi: 10.1126/sciadv.abd6280. Print 2021 Mar.

Abstract

How metabolic status controls the fates of different types of leukemia cells remains elusive. Using a SoNar-transgenic mouse line, we demonstrated that B cell acute lymphoblastic leukemia (B-ALL) cells had a preference in using oxidative phosphorylation. B-ALL cells with a low SoNar ratio (SoNar-low) had enhanced mitochondrial respiration capacity, mainly resided in the vascular niche, and were enriched with more functional leukemia-initiating cells than that of SoNar-high cells in a murine B-ALL model. The SoNar-low cells were more resistant to cytosine arabinoside (Ara-C) treatment. cyclic adenosine 3',5'-monophosphate response element-binding protein transactivated pyruvate dehydrogenase complex component X and cytidine deaminase to maintain the oxidative phosphorylation level and Ara-C-induced resistance. SoNar-low human primary B-ALL cells also had a preference for oxidative phosphorylation. Suppressing oxidative phosphorylation with several drugs sufficiently attenuated Ara-C-induced resistance. Our study provides a unique angle for understanding the potential connections between metabolism and B-ALL cell fates.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cytarabine / metabolism
  • Cytarabine / pharmacology
  • Cytidine Deaminase / genetics
  • Cytidine Deaminase / metabolism
  • Mice
  • Mice, Transgenic
  • Oxidative Phosphorylation*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma*

Substances

  • Cytarabine
  • Cytidine Deaminase